133 related articles for article (PubMed ID: 38505910)
21. Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations.
Zauderer MG; Bott M; McMillan R; Sima CS; Rusch V; Krug LM; Ladanyi M
J Thorac Oncol; 2013 Nov; 8(11):1430-3. PubMed ID: 24128712
[TBL] [Abstract][Full Text] [Related]
22. XRCC1 and ERCC1 variants modify malignant mesothelioma risk: a case-control study.
Betti M; Ferrante D; Padoan M; Guarrera S; Giordano M; Aspesi A; Mirabelli D; Casadio C; Ardissone F; Ruffini E; Betta PG; Libener R; Guaschino R; Matullo G; Piccolini E; Magnani C; Dianzani I
Mutat Res; 2011 Mar; 708(1-2):11-20. PubMed ID: 21277872
[TBL] [Abstract][Full Text] [Related]
23. Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas.
Kang HC; Kim HK; Lee S; Mendez P; Kim JW; Woodard G; Yoon JH; Jen KY; Fang LT; Jones K; Jablons DM; Kim IJ
Oncotarget; 2016 Feb; 7(7):8321-31. PubMed ID: 26824986
[TBL] [Abstract][Full Text] [Related]
24. Circulating microRNAs found dysregulated in ex-exposed asbestos workers and pleural mesothelioma patients as potential new biomarkers.
Bononi I; Comar M; Puozzo A; Stendardo M; Boschetto P; Orecchia S; Libener R; Guaschino R; Pietrobon S; Ferracin M; Negrini M; Martini F; Bovenzi M; Tognon M
Oncotarget; 2016 Dec; 7(50):82700-82711. PubMed ID: 27716620
[TBL] [Abstract][Full Text] [Related]
25. Genetic variants associated with increased risk of malignant pleural mesothelioma: a genome-wide association study.
Matullo G; Guarrera S; Betti M; Fiorito G; Ferrante D; Voglino F; Cadby G; Di Gaetano C; Rosa F; Russo A; Hirvonen A; Casalone E; Tunesi S; Padoan M; Giordano M; Aspesi A; Casadio C; Ardissone F; Ruffini E; Betta PG; Libener R; Guaschino R; Piccolini E; Neri M; Musk AW; de Klerk NH; Hui J; Beilby J; James AL; Creaney J; Robinson BW; Mukherjee S; Palmer LJ; Mirabelli D; Ugolini D; Bonassi S; Magnani C; Dianzani I
PLoS One; 2013; 8(4):e61253. PubMed ID: 23626673
[TBL] [Abstract][Full Text] [Related]
26. Upcoming epidemic of asbestos-related malignant pleural mesothelioma in Taiwan: A prediction of incidence in the next 30 years.
Lin RT; Chang YY; Wang JD; Lee LJ
J Formos Med Assoc; 2019 Jan; 118(1 Pt 3):463-470. PubMed ID: 30072200
[TBL] [Abstract][Full Text] [Related]
27.
Cheng YY; Mok E; Tan S; Leygo C; McLaughlin C; George AM; Reid G
Dis Markers; 2017; 2017():2536187. PubMed ID: 29386699
[TBL] [Abstract][Full Text] [Related]
28. Physician requests by patients with malignant pleural mesothelioma in Japan.
Nagamatsu Y; Oze I; Aoe K; Hotta K; Kato K; Nakagawa J; Hara K; Kishimoto T; Fujimoto N
BMC Cancer; 2019 Apr; 19(1):383. PubMed ID: 31023248
[TBL] [Abstract][Full Text] [Related]
29. A molecular phenotypic map of malignant pleural mesothelioma.
Di Genova A; Mangiante L; Sexton-Oates A; Voegele C; Fernandez-Cuesta L; Alcala N; Foll M
Gigascience; 2022 Dec; 12():. PubMed ID: 36705549
[TBL] [Abstract][Full Text] [Related]
30. Large-scale analysis of BAP1 expression reveals novel associations with clinical and molecular features of malignant pleural mesothelioma.
De Rienzo A; Chirieac LR; Hung YP; Severson DT; Freyaldenhoven S; Gustafson CE; Dao NT; Meyerovitz CV; Oster ME; Jensen RV; Yeap BY; Bueno R; Richards WG
J Pathol; 2021 Jan; 253(1):68-79. PubMed ID: 32944962
[TBL] [Abstract][Full Text] [Related]
31. Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X.
Joseph NM; Chen YY; Nasr A; Yeh I; Talevich E; Onodera C; Bastian BC; Rabban JT; Garg K; Zaloudek C; Solomon DA
Mod Pathol; 2017 Feb; 30(2):246-254. PubMed ID: 27813512
[TBL] [Abstract][Full Text] [Related]
32. [Research progress on pathogenesis of malignant mesothelioma].
Mei W; Zhang YP; Yang SJ
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2024 Mar; 42(3):232-240. PubMed ID: 38538248
[TBL] [Abstract][Full Text] [Related]
33. Clinical and prognostic features of erionite-induced malignant mesothelioma.
Demirer E; Ghattas CF; Radwan MO; Elamin EM
Yonsei Med J; 2015 Mar; 56(2):311-23. PubMed ID: 25683976
[TBL] [Abstract][Full Text] [Related]
34. Malignant pleural mesothelioma: Germline variants in DNA repair genes may steer tailored treatment.
Sculco M; La Vecchia M; Aspesi A; Pinton G; Clavenna MG; Casalone E; Allione A; Grosso F; Libener R; Muzio A; Rena O; Baietto G; Parini S; Boldorini R; Giachino D; Papotti M; Scagliotti GV; Migliore E; Mirabelli D; Moro L; Magnani C; Ferrante D; Matullo G; Dianzani I
Eur J Cancer; 2022 Mar; 163():44-54. PubMed ID: 35032816
[TBL] [Abstract][Full Text] [Related]
35. Dysregulated Expression of the MicroRNA miR-137 and Its Target YBX1 Contribute to the Invasive Characteristics of Malignant Pleural Mesothelioma.
Johnson TG; Schelch K; Cheng YY; Williams M; Sarun KH; Kirschner MB; Kao S; Linton A; Klebe S; McCaughan BC; Lin RCY; Pirker C; Berger W; Lasham A; van Zandwijk N; Reid G
J Thorac Oncol; 2018 Feb; 13(2):258-272. PubMed ID: 29113949
[TBL] [Abstract][Full Text] [Related]
36. Increased Standardised Incidence Ratio of Malignant Pleural Mesothelioma in Taiwanese Asbestos Workers: A 29-Year Retrospective Cohort Study.
Lin CK; Chang YY; Wang JD; Lee LJ
Biomed Res Int; 2015; 2015():678598. PubMed ID: 26290869
[TBL] [Abstract][Full Text] [Related]
37. Genomics and Functional Genomics of Malignant Pleural Mesothelioma.
Cakiroglu E; Senturk S
Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32882916
[TBL] [Abstract][Full Text] [Related]
38. Genetic predisposition for malignant mesothelioma: A concise review.
Betti M; Aspesi A; Sculco M; Matullo G; Magnani C; Dianzani I
Mutat Res Rev Mutat Res; 2019; 781():1-10. PubMed ID: 31416570
[TBL] [Abstract][Full Text] [Related]
39. Malignant peritoneal mesotheliomas of rats induced by multiwalled carbon nanotubes and amosite asbestos: transcriptome and epigenetic profiles.
Reamon-Buettner SM; Rittinghausen S; Klauke A; Hiemisch A; Ziemann C
Part Fibre Toxicol; 2024 Jan; 21(1):3. PubMed ID: 38297314
[TBL] [Abstract][Full Text] [Related]
40. Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition.
Srinivasan G; Sidhu GS; Williamson EA; Jaiswal AS; Najmunnisa N; Wilcoxen K; Jones D; George TJ; Hromas R
Cancer Chemother Pharmacol; 2017 Oct; 80(4):861-867. PubMed ID: 28756516
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
